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Chemotherapy resistance is still a great challenge to the management of ovarian cancers. Using 
SKOV3/ADR or COC1/DDP subline as a model of adriamycin- or cisplatin-resistance, ultrasonic 
chemosensitization was investigated. The addition of noncytotoxic insonation led to a higher cell-death 
rate as compared with a drug alone. Ultrasound sensitized chemotherapy via increasing intracellular 
drug accumulation, enhancing drug-induced apoptosis and decreasing the threshold dose for cell 
apoptosis/necrosis. Ultrasound exposure enhanced cisplatin-induced DNA breakages in COC1/DDP 
cells but did not decrease the level of glutathione-S-transferase. Chemosensitization attributable to 
insonation was mostly mediated by cavitation. Ultrasonic chemotherapy had the property of a targeted 
treatment, in that the dose-anticancer effect and dose-toxicity curves differed from those in 
conventional chemotherapy. The findings indicated that ultrasound was a non-drug modality for 
sensitizing chemotherapy in refractory ovarian cancers. 
 





Ovarian cancer is the leading cause of death in 
gynecological malignancies. Of those factors which lead 
to the failure of treatment, the development of 
chemoresistance plays a determining role. Overcoming 
chemoresistance can efficiently deactivate cancer cells, 
thereby improving the clinical outcomes. 
A chemical chemosensitizer commonly disappoints 
oncologists due to severe toxicities to noncancerous 
tissues (Morjani and Madoulet, 2010; Takara et al., 
2006). A non-drug modality is therefore an alternative. 
We reported the use of ultrasound to sensitize 
chemotherapy in chemoresistant ovarian cancers in this 
note. Chemotherapy resistance and ultrasonic therapy 
were theoretically introduced, and then experimental 
findings from two chemoresistant human ovarian cancer 
cell sublines, SKOV3/ADR and COC1/DDP, were briefly 
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Platinum- and multidrug-resistance (MDR) are the two most 
frequent phenotypes in ovarian cancers (Arts et al., 2000). 
Adriamycin-resistance is a typical MDR. Mechanisms of 
chemotherapy resistance are briefly summarized in Table 1 
(Agarwal and Kay, 2003; Itamochi et al., 2008; Piulats et al., 2009). 
Many chemical chemosensitizers have been tested in vitro and in 
vivo. These include, but not limit to: (i) calcium channel blocker, (ii) 
immunosupressant, (iii) hormone agonist and (iv) antifugal agent 
(Morjani and Madoulet, 2010; Takara et al., 2006). Briefly, clinical 
outcomes disappoint oncologists. Severe toxicities to noncancerous 




Ultrasonic cancer therapy 
 
Ultrasound induces thermal and nonthermal (mechanical effect and 
cavitation) effects in the insonated tissues. These effects occur 
concurrently, but do not work in the same way. A specific 
mechanism plays a leading role in a specific biological response 
(Yu et al., 2004a). Ultrasound heats tissues when the intensity is 
high enough with long exposure-duration. Cavitation, the formation 
and/or activity of gas-filled  bubbles  in  sonicated  medium,  causes  




Table 1. Mechanisms of platinum- and adriamycin-resistance in ovarian cancers. 
 
Type Mechanisms 
Adriamycin resistance (MDR) Decrease of intracellular drug level 
 P-glycoprotein (P-gp) 
 Multidrug resistance protein (MRP) 
 Lung resistance protein (LRP) 
 Malfunction of apoptosis 
 BCL-2 family 
 p53 
 Alteration of drug target 
 Topoisomerase 
Platinum resistance Decrease of intracellular drug level 
 Lung resistance protein (LRP) 
 Inactivation of a drug 
 Glutathione-S-transferase (GST) 
 Glutathione (GSH) 
 Gamma-glutamyl cysteine synthetase 
 Enhancement of DNA repair   
 ERCC1 
   XPA 
 DNA-polymerase 
 Defect of apoptosis 
 BCL-2 family 
 p53 





 Growth factor signaling 





microstreaming and microjet (with a velocity of 1000 m/s), which 
create shear force thus distorting the surrounding objects. 
Cavitation leads to localized high temperature (104-106 K) and high 
pressure (104 atmospheres) (Paliwal and Mitragotri, 2006). Such an 
extreme condition leads to the production of free radicals. 
Bioeffects depend on both ultrasound and the property of tissues. 
Therapeutic ultrasound operates within the range of nonlinear 
acoustics, and the biological response varies considerably between 
tissue types and individuals. Thus, the acoustic parameter must be 
individually selected according to the therapeutic goal. Tissue 
changes comprise structural and functional profiles. Structural 
alterations vary from just detectable injury to immediate cell death, 
and cell function can be up- or down-regulated (Yu et al., 2004a). 
The uses of ultrasound for cancer treatment are listed in Table 2 
(ter Haar, 2007; Yu et al., 2004a, 2006). Only ultrasonic 
chemotherapy will be discussed in this paper. Sonochemotherpy 
(ultrasonic chemotherapy) is the use of ultrasound to enhance a 
cytotoxic agent (Yu and Zhang, 2010). This technique 
equipotentially kills cells with a lower dose when compared with 
conventional chemotherapy. Thus, sonochemotherapy improves 
the anticancer effect whilst decreasing toxicity. Cavitation plays the 
determining role in that reactive species  and  shear  force  damage 
cell membrane including pore formation (with a size of up to 3-5 
m) (Liang et al., 2010; Zhao et al., 2008). These permeabilize cell 
membrane and vessels favoring the influx of drugs into the lesion 
since ultrasound can be focused on a predetermined volume within 
the body without harming overlying/surrounding tissues. The use of 
ultrasound to enhance an antincancer drug has been reviewed in 
several published papers (Liang et al., 2010; Paliwal and Mitragotri, 





Cells, ultrasound exposure and statistics 
 
Ovarian carcinoma cell sublines SKOV3/ADR and COC1/DDP were 
used as models of adriamycin- and cisplatin-resistance, 
respectively. The resistant indexes, determined by the ratio of 50% 
inhibiting concentration, were 6.37 for SKOV3/ADR and 6.50 for 
COC1/DDP (Yu et al., 2003; Zhou et al., 1996). Experimental data 
were statistically processed with the analysis of variance and t test.  
The mode of drug followed by insonation was used. Ultrasound 
exposure  was  performed  as  described  previously  (Zhou  et   al.,  




Table 2. List of ultrasonic therapies for cancers. 
 
Therapeutic modality  Leading role  Dosimetry 
High intensity focused ultrasound Heat Temperature rise (>56 °C) 
Ultrasonic hyperthermia Heat Temperature rise (<50 °C) 
Gene transfer/expression Cavitation Free radicals 
  Passive cavitation 
Gene expression using temperature-depended 
promotor 
Heat Temperature rise (promotor 
specific) 
Prodrug therapy Cavitation Free radicals 
Gene-directed prodrug therapy Heat Temperature rise (promotor 
specific) 
Sonodynamic therapy Cavitation Free radicals 
Ultrasonic chemotherapy (Sonochemotherapy) Cavitation Free radicals 







Figure 1. Cell-death rate of SKOV3/ADR cells. The rate was 
increased in group ADR+US. ADR, cells were exposed to 
adriamycin; ADR+US, cells were treated with adriamycin followed 




2011). The insonation parameter (frequency, intensity and 
exposure duration) was individually selected according to cells’ 
response. A level which alone produced no cytotoxicity was used, 
which did not lead to an obvious temperature-rise (temperature in 





SKOV3/ADR cells were subjected to adriamycin in group ADR, and 
to adriamycin followed by insonation (0.24 MHz, 5.76 W/cm2 for 30 
s) in group ADR + US. Drugs were washed away after 4 h, and cell 
viability was determined with a tetrazolium assay at 72nd h. A 
higher cell-death rate was detected in group ADR + US (Figure 1) 
(Yu et al., 2003). 
The decrease of intracellular drug accumulation was one of the 
most important mechanisms of adriamycin-resistance (Itamochi et 
al., 2008; Takara et al., 2006). Thus, the intracellular drug level was 
determined with a 1.5-h-exposure assay. Intracellular drug 
accumulation in group ADR + US was higher than that in group 
ADR at 2 g/ml adriamycin (0.2194 ± 0.0030 vs. 0.2446 ± 0.0100 
g, p = 0.0139) (Yu et al., 2003). 
The overexpression of mdr1 gene pumped out drugs decreasing 
the intracellular drug level, and many chemosensitizers overcame 
resistance via down-regulating the gene expression (Takara et al., 
2006). mdr1 was assayed with reverse-transcription polymerase 
chain reaction. The data did not show that ultrasound modulated 
the expression of mdr1 in SKOV3/ADR cells (0.63 ± 0.20 vs. 0.61 ± 
0.17, p = 0.8965) (Figure 2). 
Insufficient apoptosis resulted in chemoresistance (Agarwal and 
Kay, 2003). Cell apoptosis was quantitatively determined by 
measuring the sub-G1 peak with flow cytometry. Apoptosis rates in 
group ADR + US were higher than those in group ADR at 48th, 
72nd and 96th h (Figure 3) (Yu et al., 2004b).  
Chemoresistant tumors were established using subrenal capsule 
transplantation of  cell-clot  into  female  BALB/C  mice.  Adriamycin  






Figure 2. The expression of mdr1 gene determined 
with reverse-transcription polymerase chain reaction. 






Figure 3. Apoptosis rates in SKOV3/ADR cells at 48th, 72nd and 
96th h. The use of ultrasound enhanced adriamycin-induced 
apoptosis. ADR, cells were exposed to adriamycin; ADR+US, cells 




were injected peritoneally (8 mg/kg). Insonation (0.24 MHz, 7.84 
W/cm2 for 10 min) was performed 15 min after administrating drug 
since the concentration in kidney reached the peak at that time. 
Treatment was performed at days 2, 3, 5 and 6, and the tumor 
volume was calibrated under a stereomicroscope at day 7. The 
volume in group ADR + US was smaller than that in group ADR, 






COC1/DDP cells were exposed to cisplatin in group DDP, and 
insonation (0.8 MHz, 2 W/cm2 for 10 s) was added in group DDP + 
US. Chemicals were washed away after 3 h, and cell viability was 
assayed at 72nd h. The cell-death rate in group DDP+US was 
higher than that in group DDP at 5 g/ml cisplatin (69.60 ± 2.51% 
vs. 63.93 ± 1.30%, p = 0.0254). 
Intracellular cisplatin level was assayed with high performance 
liquid chromatography after 1 h exposure. Intracellular cisplatin 
accumulation was increased in group DDP + US when compared 
with group DDP (1.7320 ± 0.2140 vs. 2.3143 ± 0.0217 g, p = 
0.0201). 
Cisplatin deactivated cells via the formation of DNA crosslink 
(Agarwal and Kay, 2003). DNA damages were detected with  single 
cell gel electrophoresis. Comet tails appeared in groups DDP and 
DDP + US, and a longer tail occurred in group DDP + US (Figure 5) 
(Yu et al., 2009). 
Glutathione-S-transferase (GST) inactivated cisplatin, thereby 
protecting cancer cells (Agarwal and Kay, 2003). One of the 
strategies to treat refractory lesions was to modulate the level of 
GST in cancer tissues. Active GST was determined with an enzyme 
assay. Insonation did not decrease the GST level in COC1/DDP 






Mechanisms of chemoresistance have not been 
understood thoroughly so far. The resistance to a specific 
drug may result from several pathways and a specific 
pathway may be involved in the resistances to several 
agents; pathways overlap frequently and combined 
chemotherapy is the standard strategy for ovarian 
cancers (Rahaman et al., 2009). Thus, it is difficult to 
develop a chemical sensitizer. Either adriamycin- or 
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Figure 4. SKOV3/ADR tumor volumes after treatment. The volume 
in group ADR+US was smaller than that in group ADR indicating 
chemosensitization in vivo. ADR, tumor was exposed to 
adriamycin; US, tumor was subjected to insonation; ADR+US, 
tumor was treated with the combination of adriamycin and 







Figure 5. DNA breaks in chemoresistant cells COC1/DDP detected by 
single cell comet electrophoresis. No damages were detected in cells 
exposed to ultrasound alone (left). DNA damages occurred in cells 
subjected to cisplatin (middle) and cisplatin followed by insonation 




study, indicating that ultrasound was a potential 
therapeutic modality for refractory ovarian cancers. 
Ultrasound increased the intracellular drug levels in 
both SKOV3/ADR and COC1/DDP cells, which was one 
of the mechanisms of ultrasonic chemosensitization. The 
therapeutic efficacy of a drug is reliant on the peak 
concentration and area under the concentration-time 
curve (Fruehauf, 2002). Both of them will be increased 
with increasing intracellular drug accumulation. 
Polymerase chain reaction did not demonstrate the 
down-regulation of mdr1 gene. Cavitation permeabilizes 
cell membrane thus facilitating the transmembrane influx 
of drugs. 
An anticancer agent usually deactivates cells via 
inducing apoptosis, and the malfunction of apoptosis 
leads to chemoresistance (Agarwal and Kay, 2003). The 
addition   of   ultrasound   enhanced   adriamycin-induced 
apoptosis in SKOV3/ADR cells in this study. Apoptosis is 
realized via cytochrome C-dependent or -independent 
pathway. Cytosol cytochrome C was increased in 
insonated SKOV3/ADR cells but decreased in sonicated 
COC1/DDP ones in our previous study (Yu et al., 2005). 
Ultrasound, therefore, induced cell apoptosis via both 
approaches. Cells can also be efficiently deactivated 
through nonapoptotic pathways, which is a strategy 
against refectory cancers (Finkel, 1999). Frequently, the 
increase of apoptosis rate was not proportional to that of 
cell-death rate in ultrasonic chemotherapy, indicating the 
involvement of nonapoptotic cell dearth (Yu et al., 2006). 
The role of other modes of cell death (necrosis and 
autophage) in ultrasonic sensitization should be 
investigated. 
Cisplatin-resistant cancer cells commonly have an 
increased  capacity  of  DNA  repair,  thereby  decreasing  
 






Figure 6. The dose-anticancer effect curve 
paralleles the dose-toxicity curve in 
conventional chemotherapy (solid line). In 
ultrasonic chemotherapy, the dose-
anticancer effect curve was shifted left; and 
the dose-toxicity curve shifted right as 
cytotoxic drugs were released into cancer 
tissues directly and efficiently; toxicities to 
surrounding noncancerous tissues were 
decreased as a result of much lower drug 
level (dashed line). Sonochemotherapy was 
a targeted therapy, improving both the 




drug induced  DNA  damages  (Agarwal  and  Kay,  2003; 
Piulats et al., 2009). Insonation enhanced DNA breaks 
induced by cisplatin, where the increase of intracellular 
drug level played a role. DNA repair is a programmed 
procedure involving in many molecules. Thus, how 
ultrasound enhanced DNA damages should be explored. 
Drug inactivation diminishes the active form of a drug and 
GST is one of the most important toxinicides (Agarwal 
and Kay, 2003). GST was not impacted in this study. 
Effects of ultrasound on other detoxification molecules 
should be explored. 
Our previous investigation manifested that ultrasound 
enhanced adriamycin despite an absence of increase of 
intracellular drug level. The cell-surviving curve was 
therefore evaluated with mathematic models, and the 
data showed that ultrasound was a sensitizer. Nontoxic 
insonation sensitized a cell making it prone to being 
impaired by other cytotoxic factors. Ultrasound lowered 
the threshold for cell necrosis/apoptosis. Some cells 
befell necrosis directly in ultrasonic chemotherapy, but 
would be deactivated via triggering apoptosis in 
conventional chemotherapy (Yu et al., 2006). The 
interaction between an anticancer drug and ultrasound in 
sonochemotherapy can be a synergism, an addition or an 
antagonism; cancer type and the drug are the 
determinants of an interaction (He et al., 2011; Yu et al., 
2011). A cytotoxic agent should be carefully selected for 
a specific cancer, thus realizing an expected synergism.  
A smaller volume of SKOV3/ADR tumor suggested that 
ultrasonic sensitization was effective in vivo. How to 
perform ultrasonic chemotherapy for ovarian cancers 
should be explored. Under the guidance of medical 
images, ultrasound can be efficiently delivered into the 
lesion thereby enhancing an anticancer drug. The interval 
between drug administration and insonation should be 
optimized according to the pharmacokinetics. Ultrasound 
should be applied at the time when the drug level in 
cancer tissues is high enough and that in the adjacent 
tissues is below a critical value. Such a manner can 
improve the therapeutic effect and decrease the toxicity 
to noncancerous tissues. 
Ultrasound has excellent tissue penetration and can be 
focused on a predetermined volume within the body 
without harming overlying tissues (ter Haar, 2001). This 
suggests that cytotoxic drugs can be efficiently released 
into a lesion when using ultrasound. Sonochemotherapy 
had the property of a targeted therapy, which produced 
stronger therapeutic effects at a given dose of drug when 
compared with conventional chemotherapy. The dose-
effect curve paralleled the dose-toxicity one in common 
chemotherapy, and was shifted left in sonochemo-
therapy. Anticancer drugs were released into cancer 
tissues efficiently when applying ultrasound; thus 
surrounding noncancerous tissues were exposed to a 
much lower level of drug. This led to a right shift of the 















fore, improved both the therapeutic and safe indexes. 
Free drugs were used in this study. Drug encapsulation 
has been recently applied for ultrasonic drug delivery 
(Lentacker et al., 2009; Maeda et al., 2009). In 
chemoresistant ovarian cancer cells A2780/ADR, the 
addition of ultrasound enhanced cell-killing due to 
adriamycin micelles (Rapoport, 2004). Capsulated drugs 
can be linked to an antibody or a ligand thus improving 
the tissue selectivity. This was another modality for 
chemotherapy sensitization using ultrasound (Yu et al., 
2006).  
In summary, ultrasound provided a non-drug means for 
sensitizing chemotherapy in resistant ovarian cancers. 
This modality had the property of targeted chemotherapy, 
thereby improving both the safety and therapeutic 
efficacy. Only limited mechanisms were explored in the 
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